MAPT and Alzheimer disease: β-amyloid peptide and phosphorylated tau deposition can be detected through magnetic resonance imaging and positron emission tomography, but these methods alone cannot reliably distinguish AD from other neurodegenerative diseases and require complementary clinical assessments (Odusami et al. 2024).